[Myocardial hypertrophy due to isoproterenol. The preventive action of verapamil].
Póvoa
R
R
Universidade Federal de São Paulo, Escola Paulista de Medicina, Brasil.
Manzoli
M T
MT
Ferreira
C
C
Murad
N
N
Simões
M
M
Ferreira
C
C
Luna
B
B
D000704:Analysis of Variance; D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D006332:Cardiomegaly / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D002316:Cardiotonic Agents / Q000633:toxicity*; D004353:Drug Evaluation, Preclinical; D006321:Heart / Q000187:drug effects; D007545:Isoproterenol / Q000633:toxicity*; D008297:Male; D009206:Myocardium / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D018709:Statistics, Nonparametric; D013997:Time Factors; D014700:Verapamil / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D014700:Verapamil; D007545:Isoproterenol
Hipertrofia miocárdica pelo isoproterenol. Acção preventiva do verapamil.